接受环磷酰胺诱导的ANCA相关血管炎患者复发率及危险因素的系统综述与Meta分析
结果显示接受环磷酰胺诱导的AAV患者1年、3年、5年累积复发率分别约为12%、33%、47%,并识别出多个复发危险因素。
要点
- 接受环磷酰胺诱导的AAV患者1年、3年、5年累积复发率分别约为12%、33%、47%。
- 基线年龄与1年复发率正相关,肉芽肿性多血管炎比例与5年复发率正相关。
- 复发危险因素包括基线血清肌酐较低、诊断时PR3-ANCA阳性、ANCA升高、肾外器官受累等。
核心结论
- 接受环磷酰胺诱导的AAV患者1年、3年、5年累积复发概率分别约为12%、33%、47%。
- 早期识别复发危险因素有助于患者风险分层以实现个体化治疗。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase和Cochrane Library数据库自建库至2020年3月30日。
- 纳入队列研究和事后分析研究,估计汇总累积复发率和调整风险比(aHR)及95%置信区间(CI)。
主要发现
- 汇总1年、3年、5年累积复发率分别为0.12(95% CI 0.10-0.14)、0.33(95% CI 0.29-0.38)、0.47(95% CI 0.42-0.52)。
- Meta回归显示基线年龄与1年累积复发率正相关,肉芽肿性多血管炎比例与5年累积复发率正相关。
- 复发危险因素包括基线血清肌酐较低、诊断时蛋白酶3(PR3)-ANCA阳性、ANCA升高、肾外器官受累(包括肺、心血管、上呼吸道和胃肠道受累)、静脉(对比口服)环磷酰胺诱导、免疫抑制剂维持疗程较短、以及霉酚酸酯(对比硫唑嘌呤)维持治疗。
关键数值与推荐
- 1年累积复发率0.12(95% CI 0.10-0.14),3年0.33(95% CI 0.29-0.38),5年0.47(95% CI 0.42-0.52)。
- 复发危险因素包括基线血清肌酐较低、诊断时PR3-ANCA阳性、ANCA升高、肾外器官受累、静脉环磷酰胺诱导、维持疗程较短、霉酚酸酯维持。
临床怎么用
- 对接受环磷酰胺诱导的AAV患者,应依据复发危险因素进行风险分层以指导个体化治疗。
- 识别基线年龄、肉芽肿性多血管炎比例、PR3-ANCA阳性、ANCA升高、肾外器官受累等特征有助于早期预警复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical relapses are common in patients with ANCA-associated vasculitis (AAV). The aim of this systematic review was to estimate time-point prevalence and risk factors of relapse. METHODS: We searched PubMed, Embase, and Cochrane Library databases from their inception to March 30, 2020. Cohorts and post-hoc studies were included for the estimation of summary cumulative relapse rates (CRRs) and adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs). Sensitivity and meta-regression analyses were also performed. RESULTS: Of the 42 eligible studies, 24 studies with 6236 participants were used for the pooled analyses of CRRs. The summary 1-year, 3-year, and 5-year CRRs were 0.12 (95% CI, 0.10-0.14), 0.33 (0.29-0.38), and 0.47 (0.42-0.52), respectively. In meta-regressions, the baseline age was positively associated with 1-year CRR. The proportion of granulomatosis with polyangiitis was positively associated with 5-year CRR. Twenty-eight studies with 5390 participants were used for the meta-analysis of risk factors for relapse, including a lower level of baseline serum creatine, proteinase 3 (PR3)-ANCA positivity at diagnosis, an ANCA rise, extrarenal organ involvement (including lung, cardiovascular, upper respiratory, and gastrointestinal involvement), intravenous (vs oral) cyclophosphamide induction, a shorter course of immunosuppressant maintenance, and maintenance with mycophenolate mofetil (vs azathioprine). CONCLUSIONS: Our systematic review demonstrated that the 1-year, 3-year, and 5-year cumulative probabilities of relapse were ∼12%, 33%, and 47% in AAV patients receiving cyclophosphamide induction, respectively. Early identification of risk factors for relapse is helpful to the risk stratification of patients so as to achieve personalized treatment.
引用
- He P, Hu JP, Tian XJ, et al. Prevalence and risk factors of relapse in patients with ANCA-associated vasculitis receiving cyclophosphamide induction: a systematic review and meta-analysis of large observational studies. Rheumatology (Oxford). 2021. PMID: 33677596. doi:10.1093/rheumatology/keaa667
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。